意大利全国调查:初诊寡转移性前列腺癌的非姑息性放疗
该调查于2018年2月通过电子邮件向意大利放射肿瘤科医生发放问卷,共111人完成,旨在了解其对初诊寡转移性前列腺癌非姑息性放疗的当前观点。多数受访者每年接诊此类患者≤10例,超过80%会对前列腺及所有转移灶(多数至2-3个)行放疗,且多数认为胆碱或PSMA-PET为必需,超过50%推荐联合雄激素剥夺治疗至少12个月。
要点
- 超过80%的受访放射肿瘤科医生会对前列腺及所有转移灶行放疗,但多数仅限2-3个转移灶。
- 多数受访者认为在考虑非姑息性放疗前,胆碱或PSMA-PET检查是必需的。
- 超过50%的受访者推荐放疗联合雄激素剥夺治疗至少12个月。
核心结论
- 该调查了解了意大利放射肿瘤科医生对初诊寡转移性前列腺癌管理的当前观点,并证实其参与相关多中心研究的兴趣。
研究设计与样本
- 意大利全国性问卷调查,于2018年2月通过电子邮件发送给意大利放射肿瘤科医生,要求每家机构仅一名日常从事前列腺癌管理的医生填写;问卷共15个问题,涉及初诊寡转移性前列腺癌的管理;共111名放射肿瘤科医生完成问卷。
诊断标准与关键数值
- 大多数受访者每年接诊初诊寡转移性前列腺癌患者≤10例。
- 超过80%的受访者会对前列腺和所有转移部位行放疗,但多数仅至2-3个转移灶。
- 超过80%的医生会对淋巴结和骨继发灶均行放疗。
- 多数受访者认为在考虑非姑息性放疗前,胆碱或前列腺特异性膜抗原(PSMA)-PET是必需的。
- 超过50%的受访者推荐放疗联合雄激素剥夺治疗至少12个月。
临床应用与阅片要点
- 在随访阶段,大多数受访者建议每3-6个月进行临床检查和PSA检测,仅在生化进展时行胆碱或PSMA-PET。
- 超过90%的受访者确认有兴趣参与关于该主题的多中心研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIMS: The purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients.
METHODS: A link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC.
RESULTS: One hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2-3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3-6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject.
CONCLUSIONS: This survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management.
引用
- Timon G, Jereczek-Fossa BA, Fersino S, et al. Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey. Radiol Med. 2018. PMID: 30361923. doi:10.1007/s11547-018-0952-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。